Inibidores do SGLT-2: um passo em frente no tratamento da ICFEr

Translated title of the contribution: SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction

José Silva-Cardoso, Aurora Andrade, Dulce Brito, Jorge Ferreira, Cândida Fonseca, Marisa Peres, Fátima Franco, Brenda Moura

Research output: Contribution to journalReview articlepeer-review

Abstract

Heart failure (HF) is a major health problem with a significant impact on morbidity, mortality, quality of life and healthcare costs. Despite the positive impact of disease-modifying therapies developed over the last four decades, HF mortality and hospitalization remain high. We aim at reviewing the evidence supporting the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, as a novel strategy for HF with reduced ejection fraction (HFrEF) treatment. The consistent observation of a reduction in HF hospitalizations in type-2 diabetes cardiovascular safety trials EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58 and VERTIS raised the hypothesis that SGLT-2 inhibitors could have an impact in HF treatment. This hypothesis was first confirmed in 2019 with the DAPA-HF publication showing that dapagliflozin on top of optimized HFrEF therapy, reduced HF-hospitalizations and cardiovascular mortality. This was reinforced by the EMPEROR-Reduced publication in 2020 showing that empagliflozin on top of optimized HFrEF therapy, reduced HF-hospitalizations. Both studies established SGLT-2 inhibitors as a fourth pillar of HFrEF prognosis-modifying therapy, in addition to the gold standard triple neurohormonal modulation/blockade.

Translated title of the contributionSGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
Original languagePortuguese
JournalRevista Portuguesa de Cardiologia
DOIs
Publication statusE-pub ahead of print - 2021

Keywords

  • Canagliflozin
  • Cardiovascular mortality
  • Dapagliflozin
  • Empagliflozin
  • Ertugliflozin
  • Heart failure
  • Heart failure hospitalization
  • SGLT-2 inhibitors
  • Sotagliflozin
  • Type-2 diabetes mellitus

Fingerprint

Dive into the research topics of 'SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction'. Together they form a unique fingerprint.

Cite this